Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes

Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes

Abstract Background China is a high‐burden country for multidrug‐resistant tuberculosis/rifampin‐resistant tuberculosis (MDR/RR‐TB). Fluoroquinolones (FQs) are key drugs for the treatment of patients with MDR/RR‐TB. However, research on the resistance of FQs in Beijing is limited. Methods We collect...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wang Nenhan, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Tao LiYing, Li Qiao, Li Chuanyou, Dai Xiaowei
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Series:	Animal Models and Experimental Medicine
Subjects:	drug resistance levofloxacin moxifloxacin mycobacterium tuberculosis pre‐XDR‐TB
Online Access:	https://doi.org/10.1002/ame2.12505
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyResearch in context
by: Yousra Kherabi, et al.
Published: (2025-09-01)

The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020
by: S. A. Sterlikov, et al.
Published: (2023-04-01)

Complexation of fluoroquinolones with magnesium ions
by: V. M. Bakhtin, et al.
Published: (2022-10-01)

Communicable Episode 20: Tuberculosis today
by: Kathryn Hostettler, et al.
Published: (2025-06-01)

Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan
by: Pao -Yu Chen, et al.
Published: (2025-01-01)

Efficacy of Levofloxacin, Lomefloxacin and Moxifloxacin vs. Other Fluoroquinolones in Experimental Plague Due to FI+ and FI<sup>-</sup> Strains of Yersiniapestis in Albino Mice
by: I. V. Ryzhko, et al.
Published: (2020-05-01)

TB drug susceptibility testing in high fluoroquinolone resistance settings
by: F. Saluzzo, et al.
Published: (2024-05-01)

Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023
by: Andrei Dadu
Published: (2025-07-01)

Diagnostic accuracy of direct drug susceptibility testing of second-line antitubercular drugs
by: Kartiki Srivastava, et al.
Published: (2025-05-01)

Fluoroquinolone-Induced Aortic Injury
by: N. V. Izmozherova, et al.
Published: (2021-07-01)

Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15–49 years from 2010 to 2021: insights from the global burden of disease study 2021
by: Kunping Cui, et al.
Published: (2025-07-01)

Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
by: Kai Ling Chin, et al.
Published: (2024-01-01)

THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2017-11-01)

QT-Interval Prolongation in the Treatment of Drug-Resistant Tuberculosis
by: A. V. Kukurika
Published: (2024-03-01)

The Role of Risk Factors in the Development of Tuberculosis in Children Exposed to Rifampicin Resistant Tuberculosis
by: N. A. Nikiforenko, et al.
Published: (2021-08-01)

Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin
by: Jamal Wadi Al Ramahi, et al.
Published: (2018-10-01)

Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review
by: Michalik, Maciej, et al.
Published: (2025-06-01)

Frequency and Structure of Drug Resistance of M. tuberculosis in Pulmonary and Extrapulmonary Tuberculosis
by: P. K. Yablonskiy, et al.
Published: (2024-03-01)

Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review
by: Salman Daneshi, et al.
Published: (2025-08-01)

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01)

Evaluation of the Gene Xpert Mycobacterium tuberculosis/resistance to rifampicin assay in rapid diagnosis of tuberculosis and identification of rifampin resistance in tuberculous patients
by: Amal H.G. Hamed, et al.
Published: (2025-01-01)

TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01)

Investigating the Mutations in atpE and Rv0678 Genes in Mycobacterium Tuberculosis Clinical Isolates
by: Nahid Madadi-Goli1, 2, 3, et al.
Published: (2023-12-01)

Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo
by: Breli Bonheur Ngouama, et al.
Published: (2025-05-01)

Missed rifampicin and isoniazid resistance by commercial molecular assays
by: L Richards, et al.
Published: (2024-07-01)

Topical Fluoroquinolones: Current Perspectives
by: Sayali Pradhan, et al.
Published: (2015-04-01)

Xpert MTB/XDR Assay for Detection of Resistance to Isoniazid, Fluoroquinolone, Aminoglycoside, and Ethionamide Among Patients with Pulmonary Tuberculosis in Bangladesh
by: S. M. Mazidur Rahman, et al.
Published: (2025-03-01)

Assessment of Rifampicin Resistance in Presumptive Tuberculosis Cases at Dadeldhura Hospital of Sudurpaschim Province of Nepal
by: Madan Singh Bohara
Published: (2025-02-01)

IN VITRO ACTION OF THE DRUG CANDIDATE OF PBTZ169, HYDROCHLORIDE ACTION IN RESPECT OF CLINICAL STRAINS OF MYCOBACTERIUM TUBERCULOSIS WITH EXTENSIVE DRUG RESISTANCE
by: L. N. Chernousova, et al.
Published: (2016-09-01)

XDR TB in South Africa - What lies ahead?
by: V. Thaver, et al.
Published: (2007-12-01)

Prevalence of drug resistance in clinical isolates of tuberculosis from GCC: a literature review from January 2002 to March 2013
by: Mohammed Yahya Areeshi, et al.
Published: (2014-09-01)

TUBERCULOSIS WITH CONCURRENT HIV INFECTION IN RUSSIA: STATISTICS AND CORRELATIONS
by: E. B. Tsybikova, et al.
Published: (2019-01-01)

Rifampicin resistant tuberculosis in presumptive pulmonary tuberculosis cases in Dubti Hospital, Afar, Ethiopia
by: Gebremedhin Bizayene Gebrehiwet, et al.
Published: (2019-01-01)

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
by: L. Kuksa, et al.
Published: (2025-03-01)

Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019–2023
by: Olha Konstantynovska, et al.
Published: (2025-03-01)

Characterization of drug susceptibility of Mycobacterium tuberculosis isolated from new cases of tuberculosis concurrent with HIV infection
by: G. V. Panov, et al.
Published: (2015-02-01)

Treatment results of patients with multiple and extensive drug resistance registered in 2012 in the Russian Federation and in the world
by: S. A. Sterlikov, et al.
Published: (2016-01-01)

Drug resistance in Mycobacterium tuberculosis: An evolutionary perspective and its adaptation to the lung microenvironment
by: Satyendra Shukla, et al.
Published: (2024-12-01)

GENE MUTATION PATTERNS OF RIFAMPICIN IN MULTIDRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS COMPLEX STRAINS
by: Esra Yıldırım Servi, et al.
Published: (2022-03-01)

Predictors of lethal outcome in patients with tuberculosis, resistance to rifampicin, and HIV infection
by: S. S. Saenko, et al.
Published: (2020-06-01)